Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEBRHA 2: NXT007 vs Emicizumab in Hemophilia A
NCT07416604Phase 3Recruiting
- Sponsor
- Roche
- Start
- Apr 2026
- Primary completion
- Feb 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 22
01
Overview
A Phase 3 trial of zemocimig in hemophilia A, sponsored by Roche. Started Apr 2026; status: recruiting.
02
Drugs
zemocimig
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT07416604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07416604.